MRVI Relative Valuation
MRVI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRVI is overvalued; if below, it's undervalued.
Historical Valuation
Maravai LifeSciences Holdings Inc (MRVI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 1165.74. The fair price of Maravai LifeSciences Holdings Inc (MRVI) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：3.52
Fair
-16.40
PE
1Y
3Y
5Y
Trailing
Forward
-405.93
EV/EBITDA
Maravai LifeSciences Holdings Inc. (MRVI) has a current EV/EBITDA of -405.93. The 5-year average EV/EBITDA is -8.34. The thresholds are as follows: Strongly Undervalued below -183.33, Undervalued between -183.33 and -95.84, Fairly Valued between 79.15 and -95.84, Overvalued between 79.15 and 166.65, and Strongly Overvalued above 166.65. The current Forward EV/EBITDA of -405.93 falls within the Strongly Undervalued range.
-14.70
EV/EBIT
Maravai LifeSciences Holdings Inc. (MRVI) has a current EV/EBIT of -14.70. The 5-year average EV/EBIT is 54.35. The thresholds are as follows: Strongly Undervalued below -165.46, Undervalued between -165.46 and -55.56, Fairly Valued between 164.25 and -55.56, Overvalued between 164.25 and 274.16, and Strongly Overvalued above 274.16. The current Forward EV/EBIT of -14.70 falls within the Historic Trend Line -Fairly Valued range.
2.59
PS
Maravai LifeSciences Holdings Inc. (MRVI) has a current PS of 2.59. The 5-year average PS is 4.33. The thresholds are as follows: Strongly Undervalued below 0.86, Undervalued between 0.86 and 2.59, Fairly Valued between 6.07 and 2.59, Overvalued between 6.07 and 7.80, and Strongly Overvalued above 7.80. The current Forward PS of 2.59 falls within the Undervalued range.
-35.85
P/OCF
Maravai LifeSciences Holdings Inc. (MRVI) has a current P/OCF of -35.85. The 5-year average P/OCF is 10.83. The thresholds are as follows: Strongly Undervalued below -31.76, Undervalued between -31.76 and -10.47, Fairly Valued between 32.12 and -10.47, Overvalued between 32.12 and 53.42, and Strongly Overvalued above 53.42. The current Forward P/OCF of -35.85 falls within the Strongly Undervalued range.
-19.43
P/FCF
Maravai LifeSciences Holdings Inc. (MRVI) has a current P/FCF of -19.43. The 5-year average P/FCF is 7.33. The thresholds are as follows: Strongly Undervalued below -75.26, Undervalued between -75.26 and -33.96, Fairly Valued between 48.63 and -33.96, Overvalued between 48.63 and 89.93, and Strongly Overvalued above 89.93. The current Forward P/FCF of -19.43 falls within the Historic Trend Line -Fairly Valued range.
Maravai LifeSciences Holdings Inc (MRVI) has a current Price-to-Book (P/B) ratio of 2.07. Compared to its 3-year average P/B ratio of 2.32 , the current P/B ratio is approximately -10.91% higher. Relative to its 5-year average P/B ratio of 8.99, the current P/B ratio is about -76.98% higher. Maravai LifeSciences Holdings Inc (MRVI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 5.70%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 6.99% , the current FCF yield is about -100.00% lower.
2.18
P/B
Median3y
2.32
Median5y
8.99
-13.03
FCF Yield
Median3y
5.70
Median5y
6.99
Competitors Valuation Multiple
The average P/S ratio for MRVI's competitors is 0.00, providing a benchmark for relative valuation. Maravai LifeSciences Holdings Inc Corp (MRVI) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -39.69%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MRVI decreased by 32.11% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.67 to -4.39.
The secondary factor is the Revenue Growth, contributed -39.69%to the performance.
Overall, the performance of MRVI in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Maravai LifeSciences Holdings Inc (MRVI) currently overvalued or undervalued?
What is Maravai LifeSciences Holdings Inc (MRVI) fair value?
How does MRVI's valuation metrics compare to the industry average?
What is the current P/B ratio for Maravai LifeSciences Holdings Inc (MRVI) as of Dec 05 2025?
What is the current FCF Yield for Maravai LifeSciences Holdings Inc (MRVI) as of Dec 05 2025?
What is the current Forward P/E ratio for Maravai LifeSciences Holdings Inc (MRVI) as of Dec 05 2025?